AUTHORS
Jonathan Meiman, MD, MPH, Charles W Locuson, PhD2, Emily Muns, MD3, Hui Shao, PhD4, Megan Wind-Rotolo, PhD5, Heather Tevich, MSN6, Melissa Dibacco, MD7
AFFILIATIONS
1 Fortrea Clinical Research Unit Inc., Madison, Wisconsin, United States
2 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
3 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
4 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
5 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
6 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
7 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
ABSTRACT
Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by excess erythropoiesis driven by gain-of-function mutations in Janus kinase 2 (JAK2). Patients with PV have reduced levels of hepcidin, a regulator of iron homeostasis, and hepcidin upregulation has been proposed as a strategy to restrict iron availability and control erythropoiesis. AG-236 is a novel, double-stranded, hepatocyte-targeted small interfering RNA designed to silence the expression of the transmembrane serine protease 6 gene (TMPRSS6), which encodes matriptase-2, a type 2 transmembrane serine protease that downregulates hepcidin expression. We report safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) from a phase 1, first-in-human, single ascending dose (SAD) study of AG-236 in healthy participants (NCT07075640).
Methods
In this phase 1, randomized, double-blind, placebo-controlled study, healthy participants aged 18-55 years with a body mass index of 18-32 kg/m2 received a single subcutaneous dose of AG-236 at 1.0, 3.0, or 9.0 mg/kg or placebo (6:2 AG-236:placebo). The primary objective was to evaluate safety and tolerability of AG-236, assessed by treatment-emergent adverse events (TEAEs) through postdose Day 57. Secondary endpoints included PK parameters (tmax, Cmax, t½, and area under the curve from time 0 to last quantifiable concentration [AUC0-t]) and change from baseline in serum hepcidin. Exploratory endpoints included iron metabolism markers and biomarkers of erythroid expansion.
Results
Overall, 24 participants were randomized (AG-236, n=18 [n=6 per dose]; placebo, n=6), of whom 75% were male and 62.5% were White, 20.8% Black or African American, and 16.7% Asian. Mean (standard deviation [SD]) age was 39.3 (10.6) years.
AG-236 was well tolerated at all dose levels. TEAEs occurred in 14/18 (78%) participants receiving AG-236 vs 2/6 (33%) receiving placebo. All TEAEs with AG-236 were grade 1 (61% of participants) or grade 2 (17% of participants); no serious AEs occurred and no TEAEs led to study discontinuation. Treatment-related TEAEs occurred in 10/18 (56%) participants receiving AG-236 (all grade 1, except two grade 2 events of decreased neutrophil count reported in a single participant) vs 0/6 (0%) receiving placebo. The most frequent treatment-related TEAEs with AG-236 were injection-site–related events (7/18 [39%] participants).
For plasma PK, mean tmax, Cmax, and t½ were similar across doses: mean (SD) tmax was 5.7 (3.2), 5.3 (3.7), and 4.0 (1.3) h, Cmax was 158 (41.0), 497 (148), and 2510 (859) ng/mL, and t½ was 5.4 (2.4), 5.0 (1.7), and 5.5 (1.5) h with AG-236 1.0, 3.0, and 9.0 mg/kg, respectively. AUC0‑t increased with dose level, with a trend toward greater than dose-proportional exposure (AUC0–t slope, 1.24; no statistically significant deviation from proportionality by regression).
In the AG-236 treatment groups, serum hepcidin levels increased from baseline as early as Day 8. By Day 29, mean (SD) change from baseline was 18.9 (12.8), 10.3 (21.8), and 24.1 (11.1) µg/L with AG-236 1.0, 3.0, and 9.0 mg/kg, respectively, vs –1.3 (3.7) µg/L with placebo. Hepcidin elevations were consistent through study Day 57. Reductions in mean (SD) serum iron and transferrin saturation (TSAT) were observed across all AG-236 dose groups at Day 29 (serum iron: –8.8 [2.2], –12.2 [7.0], –8.6 [4.1], and –4.4 [4.4] µmol/L; TSAT: –18.0% [5.5%], –20.8% [8.4%], –15.3% [5.6%], and –6.7% [6.5%] for AG-236 1.0, 3.0, and 9.0 mg/kg and placebo, respectively), and were consistent through Day 57, reflecting decreased circulating iron availability. Mean (SD) hemoglobin (Hb) and hematocrit (Hct) decreased from baseline across AG-236 dose groups, with the largest decreases generally observed at Day 57 (Hb: –9.8 [8.8], –16.3 [8.3], –16.2 [9.4], and 0.0 [5.6] g/L; Hct: –1.3% [3.0%], –3.5% [2.7%], –2.9% [2.9%], and +0.9% [1.8%] for AG-236 1.0, 3.0, and 9.0 mg/kg and placebo, respectively). Effects of AG-236 on serum iron, TSAT, Hb, and Hct were sustained through postdose Month 6.
Conclusions
In this SAD study, AG-236 was well tolerated with no serious AEs and no dose-limiting toxicities. AG-236 administration produced sustained hepcidin increases and decreased circulating iron availability (per reduced serum iron and TSAT) with a plateau at 3.0 and 9.0 mg/kg, suggesting maximized PD activity consistent with TMPRSS6 silencing. These data support further clinical investigation of AG-236 in patients with PV.
DISCLOSURES
Jonathan Meiman, MD, MPH: Fortrea Clinical Research Unit Inc. - Current Employment